Waltermire Robert E.'s Form 4 filing
Madrigal Pharmaceuticals, Inc. (MDGL) · filed Jun 18, 2024
- Accession no.
- 0000950170-24-075221
- Filed
- Jun 18, 2024
- Trade date
- Jun 14, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $532.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Waltermire Robert E.CIK 0001876996 | Officer (Senior VP, Chief Pharma Dev.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock | MOption exerciseAcquired | +1,900 | $87.09 | +$165,471 | 7,400 | Direct | |
| Jun 14, 2024 | Common Stock | SSaleDisposed | −1,900 | $280.00 | −$532,000 | 5,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Stock Option (Right to Buy) | MOption exerciseDisposed | −1,900 | $0.00 | $0 | 10,350 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.